Bio-Rad Laboratories Inc (BIO)

Currency in USD
272.18
-4.62(-1.67%)
Closed·
After Hours
270.00-2.18(-0.80%)
·
BIO Scorecard
Full Analysis
Management has been aggressively buying back shares
BIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
270.97278.74
52 wk Range
211.43387.99
Key Statistics
Prev. Close
272.18
Open
275.66
Day's Range
270.97-278.74
52 wk Range
211.43-387.99
Volume
309.16K
Average Volume (3m)
364.87K
1-Year Change
-17.19%
Book Value / Share
261.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
326.50
Upside
+19.96%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Bio-Rad Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Bio-Rad Laboratories Inc Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc SWOT Analysis


Financial Resilience
Bio-Rad demonstrates robust financial health with strong EBITDA and current ratio, surpassing estimates despite market headwinds
Tech Advancements
Explore Bio-Rad's digital droplet PCR technology resurgence and its potential impact on revenue expansion and market positioning
Operational Challenges
Delve into Bio-Rad's strategic responses to product launch delays and macroeconomic pressures in the Life Science Tools secto
Growth Prospects
Analyst targets suggest up to 21% upside, with price ranges from $400 to $469, reflecting confidence in Bio-Rad's margin expansion potential
Read full SWOT analysis

Bio-Rad Laboratories Inc Earnings Call Summary for Q2/2025

  • Bio-Rad's Q2 2025 EPS of $2.61 beat forecasts by 50.87%, with revenue of $651.6M exceeding expectations by 5.92%
  • Despite strong results, stock fell 3.25% in aftermarket trading amid broader market trends and company-specific challenges
  • Company projects flat to 1% growth in full-year currency-neutral revenue, with gross margins between 53.5% and 54.5%
  • Expansion of digital PCR portfolio continues, while facing challenges in Chinese market and fluctuating academic research budgets
  • CEO emphasizes resilience and business advancement, focusing on customer retention and market expansion in digital PCR
Last Updated: 01/08/2025, 01:24
Read Full Transcript

Compare BIO to Peers and Sector

Metrics to compare
BIO
Peers
Sector
Relationship
P/E Ratio
22.7x−3.9x−0.5x
PEG Ratio
0.180.430.00
Price/Book
1.0x1.2x2.6x
Price / LTM Sales
2.8x4.0x3.3x
Upside (Analyst Target)
20.3%50.6%42.8%
Fair Value Upside
Unlock14.4%6.5%Unlock

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 326.50
(+19.96% Upside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
2.61 / 1.73
Revenue / Forecast
651.60M / 615.20M
EPS Revisions
Last 90 days

BIO Income Statement

People Also Watch

56.39
ATKR
-26.34%
84.95
QRVO
-0.26%
24.17
COLB
+1.21%
57.09
AAP
+6.65%
49.21
DIOD
-0.51%

FAQ

What Stock Exchange Does Bio-Rad Labs Trade On?

Bio-Rad Labs is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Bio-Rad Labs?

The stock symbol for Bio-Rad Labs is "BIO."

What Is the Bio-Rad Labs Market Cap?

As of today, Bio-Rad Labs market cap is 7.24B.

What Is Bio-Rad Labs's Earnings Per Share (TTM)?

The Bio-Rad Labs EPS (TTM) is 11.49.

When Is the Next Bio-Rad Labs Earnings Date?

Bio-Rad Labs will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is BIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bio-Rad Labs Stock Split?

Bio-Rad Labs has split 4 times.

How Many Employees Does Bio-Rad Labs Have?

Bio-Rad Labs has 7700 employees.

What is the current trading status of Bio-Rad Labs (BIO)?

As of 06 Aug 2025, Bio-Rad Labs (BIO) is trading at a price of 272.18, with a previous close of 272.18. The stock has fluctuated within a day range of 270.97 to 278.74, while its 52-week range spans from 211.43 to 387.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.